Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Clinical trial NCT06927986 · RECRUITING

Trial details

NCT number: NCT06927986
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

EGFR-mutated Locally Advanced or Metastatic NSCLC

Start date: 2025-03-30
Primary completion: 2026-07-30
Enrollment: 380

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.